期刊文献+

替加环素对多重耐药鲍曼不动杆菌的体外抗菌活性的相关研究

下载PDF
导出
摘要 目的研究替加环素对多重耐药鲍曼不动杆菌的体外抗菌活性,以指导临床合理使用抗生素。方法:收集本院临床标本分离的78株多重耐药鲍曼不动杆菌进行细菌鉴定,并采用纸片扩散法(KB法)对替加环素、美罗培南、头孢哌酮舒巴坦、头孢他啶进行体外药敏试验,观察4种药物的敏感性和耐药性。结果:替加环索对多重耐药鲍曼不动杆菌的敏感性(66.67%)显著高于美罗培南(34.62%)、头孢哌酮舒巴坦(7.69%)、头孢他啶(10.26%),(P〈0.05);耐药性(0.00%)显著低于美罗培南(43.59%)、头孢哌酮舒巴坦(71.79%)、头孢他啶(69.23%),P〈0.05。结论:替加环素对多重耐药鲍曼不动杆菌有较高的抗菌活性,可作为临床首选治疗药物。 Objective To study the for add ring element of multiple drug resistance of acinetobacter baumannii in vitroantimicrobial activity, and to guide clinical rational use of antibiotics. Methods: collected in our hospital clinical specimens of 78multiple drug-resistant strains of isolated bacteria identification of acinetobacter baumannii, and using the disc diffusion method(KB) to add ring for element, beauty eaecalis, cefoperazone shu temple, cephalosporins he totally susceptibility test in vitro,observe the sensitivity of the four drugs and drug resistance. Results: for add ring element of multiple drug resistance ofaeinetobacter baumannii sensitivity (66.67%) is significantly higher than the United States e.faecalis, and cefoperazone shu bajotham, cephalosporins he organism (34.62%, 7.69%, 10.26%), (P 〈 0.05); Resistance (0.00%) was significantly lower than theUnited States e,faecalis and cefoperazone shu temple, and he totally cephalosporin ( 43.59%, 71.79%, 69.23% ) ( P 〈 0.05).Conclusion: for ring element of multiple drug resistant acinetobacter baumannii have higher antimicrobial activity, can be usedas a cl'inical choice for treatment.
出处 《世界中医药》 CAS 2016年第B03期751-752,共2页 World Chinese Medicine
关键词 替加环素 鲍曼不动杆菌 多重耐药菌 体外抗菌活性 Tigecycline Acinetobacter baumannii Multidrug drug resistant Vitro activity
  • 相关文献

参考文献8

二级参考文献81

  • 1王辉,郭萍,孙宏莉,杨启文,陈民钧,朱元珏,徐英春,谢秀丽.碳青霉烯类耐药的不动杆菌分子流行病学及其泛耐药的分子机制[J].中华检验医学杂志,2006,29(12):1066-1073. 被引量:237
  • 2杨秀捷,张晨,齐文升,蓝海涛,王硕,杨忆熙,赵昕,叶锡鲁,马荣.重症加强治疗病房鲍曼不动杆菌耐药性分析及其与中医证候的关系[J].中国中西医结合急救杂志,2007,14(4):222-224. 被引量:22
  • 3卫生部合理用药专家委员会.中国医师药师临床用药指南.重庆:重庆出版社,2009:103-105.
  • 4Clinnical and Laboratory Standards Institute. M7-A7 Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. 7th ed. Approved standard. Wayne, PA : Clinical and Laboratory Standardslnstitute ,2006.
  • 5Barry AL, Jones RN. Criteria for disk susceptibility tests and quality control guidelines for the cefoperazone-sulbactam combination. J Clin Microbial,1988, 26 : 13-17.
  • 6Clinnical and Laboratory Standards Institute. M2-A9 Performance standards for antimicrobial disk susceptibility tests-Ninth edition; Approved standard. Wayne, PA : Clinical and Laboratory Standardslnstitute, 2006.
  • 7Clinnical and Laboratory Standards Institute. M100-S18 Performance standards for antimicrobial susceptibility testing; Eteenth informational supplement. Wayne, PA: Clinical and Laboratory Standardslnstitute ,2008.
  • 8Turnidge J, Paterson DL. Setting and revising antibacterial susceptibility breakpoints. Clin Microbiol Rev, 2007,20: 391- 408.
  • 9Higgins PG, Wisplinghoff H, Stefanik D, et al. In vitro activities of the β-lactamase inhibitors clavulanic acid, sulbactam, and tazobactam alone or in combination with β-lactams against epidemiologically characterized multidrug-resistant Acinetobacter baumannii strains. Antimicrob Agents Chemother, 2004, 48: 1586-1592.
  • 10Karageorgopoulos DE, Falagas ME. Current control and treatment of multidrug-rcsistant Acinetobacter baumannii infections. Lancet Infect Dis, 2008,8:751-762.

共引文献120

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部